Clinical trials: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Extensive Stage Small Cell Lung Cancer
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
The efficacy of PD-1/PD-L1 combined with chemotherapy in the treatment of extensive small-cell lung cancer is still unsatisfactory. PD-1/PD-L1 combined with chemotherapy and anti-angiogenic drugs may achieve better efficacy.
- Trial name
- NCT05001412
- Testing
- Camrelizumab; apatinib; carboplatin; etoposide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhou Chengzhi
Small Cell Lung Cancer
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
- Trial name
- (DeLLphi-310) (NCT06898957)
- Testing
- YL201, Tarlatamab, Durvalumab
- Where
- 36 sites in United States, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- Amgen
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- STAR-01 (NCT07501169)
- Testing
- Sacituzumab Tirumotecan and Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
Extensive-stage Small-cell Lung Cancer
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
The goal of this clinical trial is to test MGC018 in patients with relapsed or refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC).
- Trial name
- MGC018-SCLC (NCT06227546)
- Testing
- MGC018
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Small-Cell Lung Cancer
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with…
- Trial name
- TAZMAN (NCT04745689)
- Testing
- Durvalumab, AZD2811, Carboplatin
- Where
- 12 sites in United States, Poland and 2 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer Extensive Stage
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
This study intends to recruit ES-SCLC patients with response to standard first-line chemo-immunotherapy to assess the safety of receiving different doses of consolidative thoracic radiotherapy.
- Trial name
- NCT06187740
- Testing
- thoracic radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fudan University
Small Cell Lung Cancer
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain.
- Trial name
- SEZanne (NCT07155174)
- Testing
- ABBV-706, Atezolizumab, Etoposide
- Where
- 70 sites in United States, Belgium and 11 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
SCLC, Extensive Stage
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
This is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib…
- Trial name
- Aurora 005 (NCT07538271)
- Testing
- benmelstobart, Anlotinib, Carboplatin or cisplatin
- Volunteers
- 33 people
- Sponsor
- Yayi He
Extensive-stage Small-cell Lung Cancer
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive…
- Trial name
- NCT06536868
- Testing
- Tislelizumab, Etoposide, Carboplatin or Cisplatin
- Where
- 6 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Hospital of Shanxi Medical University
Extensive-stage Small Cell Lung Cancer
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.
- Trial name
- NCT04562337
- Testing
- SHR1316, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Shandong Cancer Hospital and Institute
Extensive-stage Small Cell Lung Cancer
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
This is a single-arm Phase Ib/II multicenter open-label study, with translational sub-study, of atezolizumab plus autologous dendritic cell vaccine as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- VENEZO-LUNG (NCT04487756)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection, ADC Vaccine, Carboplatin
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Instituto Oncológico Dr Rosell
Small Cell Lung Carcinoma
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with…
- Trial name
- IMpower133 (NCT02763579)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide
- Where
- 114 sites in United States, Australia and 19 more
- Volunteers
- 503 people
- Sponsor
- Hoffmann-La Roche
Small-cell Lung Cancer
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by…
- Trial name
- NCT05552846
- Testing
- thoracic radiotherapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Ruijin Hospital
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
- Trial name
- DeLLphi-305 (NCT06211036)
- Testing
- Tarlatamab, Durvalumab
- Where
- 219 sites in United States, Argentina and 27 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Extensive-stage Small-cell Lung Cancer
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not…
- Trial name
- NCT07459634
- Testing
- Lurbinectedin, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jazz Pharmaceuticals
Extensive-stage Small-cell Lung Cancer
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung…
- Trial name
- IDeate-Lung01 (NCT05280470)
- Testing
- Ifinatamab Deruxtecan (I-DXd)
- Where
- 58 sites in United States, China and 6 more
- Volunteers
- 187 people
- Sponsor
- Daiichi Sankyo
Extensive-stage Small-cell Lung Cancer
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
To evaluate the tolerability and safety of Low-dose radiotherapy combined with concurrent Chemotherapy, Toripalimab and Tifcemalimab in first-line treatment of Extensive-Stage Small Cell Lung Cancer, and to determine the RP2D.
- Trial name
- NCT06732258
- Testing
- Low-dose radiotherapy, Tifcemalimab injection, Toripalimab
- Sponsor
- Sichuan University
Extensive-stage Small-cell Lung Cancer
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Though great progress has been made in the treatment of SCLC in recent years, only two PD-L1 therapies are currently approved, treatment options are limited, and patient survival remains to be further improved.
- Trial name
- NCT05668767
- Testing
- Surufatinib Durvalizumab EP/EC
- Volunteers
- 20 people
- Sponsor
- Beijing Chest Hospital
Extensive-stage Small-cell Lung Cancer
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung…
- Trial name
- NCT05403723
- Testing
- Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Maryland, Baltimore
Lung Cancer
Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01057342
- Testing
- carboplatin, paclitaxel, vadimezan
- Where
- 12 sites in Switzerland
- Volunteers
- 17 people
- Sponsor
- Swiss Cancer Institute